Research Article
Development of Polymer and Surfactant Based Naringenin Nanosuspension for Improvement of Stability, Antioxidant, and Antitumour Activity
Table 1
Optimization parameters of NAR nanosuspensions stabilized by different concentrations of SDS and HPMC.
| Samples | Particle size (nm) (mean ± SD) | PDI (mean ± SD) | Zp (mV) (mean ± SD) |
| SDS conc. (% w/v) | | | | F1 (0.1) | 1251 ± 14.9 | 0.52 ± 0.04 | −25.9 ± 1.7 | F2 (0.5) | 674 ± 6.9 | 0.44 ± 0.02 | −34.7 ± 1.9 | F3 (1) | 460 ± 7.3 | 0.33 ± 0.03 | −40.6 ± 2.2 |
| HPMC conc. (% w/v) | | | | F4 (0.1) | 1421 ± 13.6 | 0.58 ± 0.05 | −5.8 ± 0.4 | F5 (0.5) | 760 ± 12.3 | 0.45 ± 0.03 | −7.1 ± 0.8 | F6 (1) | 372 ± 3.50 | 0.32 ± 0.04 | −8.8 ± 0.5 |
|
|
Drug : stabilizer (2 : 1) ratio; 15 homogenization cycles and pressure 1500 bar were fixed.
|